1. Home
  2. ENTA vs AVXL Comparison

ENTA vs AVXL Comparison

Compare ENTA & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

N/A

Current Price

$12.12

Market Cap

374.6M

Sector

Health Care

ML Signal

N/A

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

N/A

Current Price

$4.21

Market Cap

430.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ENTA
AVXL
Founded
1995
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
374.6M
430.9M
IPO Year
2012
2013

Fundamental Metrics

Financial Performance
Metric
ENTA
AVXL
Price
$12.12
$4.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$20.40
$22.00
AVG Volume (30 Days)
147.1K
964.1K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
29.93
N/A
EPS
N/A
N/A
Revenue
$102,814,000.00
N/A
Revenue This Year
$7.76
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.48
N/A
52 Week Low
$4.09
$2.86
52 Week High
$17.15
$13.99

Technical Indicators

Market Signals
Indicator
ENTA
AVXL
Relative Strength Index (RSI) 39.11 25.24
Support Level $12.09 N/A
Resistance Level $15.52 $4.98
Average True Range (ATR) 0.63 0.26
MACD -0.17 -0.13
Stochastic Oscillator 7.62 2.51

Price Performance

Historical Comparison
ENTA
AVXL

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Share on Social Networks: